Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 8 Neoplasms 4 Neoplasm Metastasis 3 Lung Neoplasms 3 Hematologic Neoplasms 3 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Lymphoproliferative Disorders 2 Lymphoma, Large-Cell, Anaplastic 2 Sexual Dysfunction, Physiological 1 Rare Tumor 1 Neuroblastoma 1 Lymphoma 1 Lung Diseases 1 Eunuchism 1 Erectile Dysfunction 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Brain Neoplasms 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Tumor × alectinib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡